Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University Hospital, Bonn Novartis |
---|---|
Information provided by: | University Hospital, Bonn |
ClinicalTrials.gov Identifier: | NCT00504400 |
The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 IMT). 10 patients will receive monthly injections of the drug into one eye over a period of one year.
Condition | Intervention | Phase |
---|---|---|
Type 2 Idiopathic Macular Telangiectasia |
Drug: Intravitreal injection ranibizumab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Ranibizumab in Idiopathic Macular Telangiectasia, Type 2. A Prospective Interventional Non-Randomized Study Comparing the Efficacy and Safety of Intravitreal Ranibizumab in Type 2 Idiopathic Macular Telangiectasia. |
Estimated Enrollment: | 10 |
Study Start Date: | August 2007 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: Intravitreal injection ranibizumab
Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
|
Type 2 idiopathic macular telangiectasia (type 2 IMT) is a retinal disease of unknown etiology that commonly presents with a slow decrease in visual acuity, reading difficulties and metamorphopsia in the fifth to seventh decade. Diagnosis is based on fluorescein angiography which typically reveals parafoveal leakage in the late phase and may show telangiectatic capillaries in the early phase. In a subset of patients, a proliferative stage with secondary neovascularizations may develop late in the disease course. In the past, there has been no effective treatment for the disease stages without neovascularization. Recent studies in a limited number of patients with nonproliferative disease have shown promising results after intravitreal injection of bevacizumab, an antagonist targeting vascular endothelial growth factor (VEGF). Bevacizumab resulted in a decrease of parafoveal leakage in fluorescein angiography and a decrease in retinal thickness. An increase in visual acuity was reported in a subset of patients.
The RAMA-Trial is initiated in order to investigate the effect of a ranibizumab. The safety and tolerability of this VEGF-antagonist has been extensively studied in large cohorts of patients suffering from age-related macular degeneration.
Patients with type 2 IMT will receive monthly injections over a period of one year. The above mentioned outcome measures will be assessed.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Department of Ophthalmology, University of Bonn | |
Bonn, Germany |
Principal Investigator: | Frank Holz, MD | University of Bonn, Department of Ophthalmology |
Principal Investigator: | Hendrik PN Scholl, MD, MA | University Hospital, Bonn |
Responsible Party: | University of Bonn ( University of Bonn ) |
Study ID Numbers: | CRFB002ADE04, EudraCT number 2006-006233-40 |
Study First Received: | July 18, 2007 |
Last Updated: | February 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00504400 History of Changes |
Health Authority: | Germany: Paul-Ehrlich-Institut |
macular telangiectasia parafoveal telangiectasis nonproliferative therapy |
intravitreal injection ranibizumab lucentis |
Telangiectasis Vascular Diseases |
Telangiectasis Vascular Diseases Cardiovascular Diseases |